ES2118095T3 - BENZIMIDAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION. - Google Patents

BENZIMIDAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION.

Info

Publication number
ES2118095T3
ES2118095T3 ES92101579T ES92101579T ES2118095T3 ES 2118095 T3 ES2118095 T3 ES 2118095T3 ES 92101579 T ES92101579 T ES 92101579T ES 92101579 T ES92101579 T ES 92101579T ES 2118095 T3 ES2118095 T3 ES 2118095T3
Authority
ES
Spain
Prior art keywords
benzimidazolyl
alkyl
substd
opt
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92101579T
Other languages
Spanish (es)
Other versions
ES2118095T4 (en
Inventor
Norbert Dr Dipl-Chem Hauel
Berthold Dr Dipl-Chem Narr
Uwe Dr Dipl-Chem Ries
Meel Jacques Dr Van
Wolfgang Dr Dipl-Biol Wienen
Michael Dr Dipl-Chem Entzeroth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27202166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2118095(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE4103492A external-priority patent/DE4103492A1/en
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical BOEHRINGER INGELHEIM PHARMA
Publication of ES2118095T3 publication Critical patent/ES2118095T3/en
Application granted granted Critical
Publication of ES2118095T4 publication Critical patent/ES2118095T4/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

1-Biphenylylmethyl-benzimidazole derivs. of formula (I) and their salts are new. (A) where: R1 = F, Cl, Br, 1-4C alkyl, cycloalkyl, CH2F, CHF2 or CF3 and is in the 4 position; R2 = R2 or may also be R2 when R4 = 1H-tetrazolyl; R'2 = 3-5C alkoxy substd. in the 3, 4 or 5 position by imidazolyl, or 2-5C alkoxy substd. in the 2, 3, 4 or 5 position by benzimidazolyl or tetrahydrobenzimidazolyl; R2 = e.g. (a) 2-(1-imadazolyl)ethoxy, 1-4C alkylsulphonyloxy, OSO2Ph or phenylalkylsulphonyloxy; (b) acylamino opt. N-substd. by 1-6C alkyl, Ph, cycloalkyl, phenylalkyl, cycloalkylalkyl, bicyclohexyl or biphenylyl, where acyl is 1-7C alkanoyl, 2-4C alkoxycarbonyl, 1-6C alkylsulphonyl, benzoyl, phenylsulphonyl, phenylalkylsulphonyl, naphthylsulphonyl, cycloalkylcarbonyl, phenylalkanoyl or cycloalkylalkanoyl, where phenyl rings are opt. substd. by 1-2 of F, Cl, Br, Me and OMe, or 3-oxopyridazylinyl or (l) 3-oxodihydropyridazinyl, opt. 2-substd. by alkyl or phenylalkyl and opt. further C-substd. by 1-2 alkyl gps., Het = a C- or imino-bonded 5-membered heteroaromatic ring or a C-bonded 6-membered heteroaromatic ring. (B) where: R1 = H or F, Cl, Br, 1-4C alkyl, CH2F, CHF2 or CF3 in the 5, 6 or 7 position; R2 = Het or a gp. as defined in (l) above; R3 and R4 are as defined in (A); provided that: (a) R2 is not 3-methylimidazo (4,5-b)pyridin-2-yl or 3-n-hexylimidazo(4,5-b) pyridin-2-yl in the 6 position when R1 = H, R3 = n-Pr and R4 = COOH; (b) R2 is not benzoxazol-2-yl in the 5 or 6 position when R1 = H, R3 = n-Pr or n-Bu and R4 = 1H-tetrazolyl; (c) R2 is not 1-methyl-2-benzimidazolyl in the 5 or 6 position or 1-n-butyl-2-benzimidazolyl, 1,5-dimethyl-2-benzimidazolyl or 1-methyl-5-trifluoromethyl -2-benzimidazolyl in the 6 postion when R1 = H, R3 = n-Pr and R4 = COOH; (d) R2 is not 1-methyl-2-benzimidazolyl in the 6 position when R1 = H, R3 = n-Bu and R4 = COOH or 1H-tetrazolyl; (e) R2 is not 2-benzimidazolyl in the 6 position when R1 = H, R3 = n-Bu and R4 = COOH; unless otherwise stated, alkanoyl, alkyl and alkoxy gps. are 1-3C and cycloalkyl gps. are 3-7C.
ES92101579T 1991-02-06 1992-01-31 Benzimidazoles, medicines containing these compounds and procedure for their preparation. Expired - Lifetime ES2118095T4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4103492A DE4103492A1 (en) 1991-02-06 1991-02-06 New 1-(1,4-bi:phenyl-methyl) benzimidazole(s) as angiotensin II antagonists
DE4117121A DE4117121A1 (en) 1991-02-06 1991-05-25 New 1-(1,4-bi:phenyl-methyl) benzimidazole(s) as angiotensin II antagonists
DE4137812A DE4137812A1 (en) 1991-02-06 1991-11-16 New 1-(1,4-bi:phenyl-methyl) benzimidazole(s) as angiotensin II antagonists

Publications (2)

Publication Number Publication Date
ES2118095T3 true ES2118095T3 (en) 1998-09-16
ES2118095T4 ES2118095T4 (en) 2011-04-07

Family

ID=27202166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92101579T Expired - Lifetime ES2118095T4 (en) 1991-02-06 1992-01-31 Benzimidazoles, medicines containing these compounds and procedure for their preparation.

Country Status (26)

Country Link
EP (1) EP0502314B1 (en)
JP (1) JP2709225B2 (en)
AT (1) ATE166346T1 (en)
BG (1) BG62309B2 (en)
CA (1) CA2060624C (en)
CH (1) CH0502314H1 (en)
CZ (1) CZ287607B6 (en)
DE (2) DE59209330C5 (en)
DK (1) DK0502314T3 (en)
ES (1) ES2118095T4 (en)
FI (1) FI105547B (en)
HK (1) HK1011145A1 (en)
HR (1) HRP940752B1 (en)
HU (2) HU217084B (en)
IE (1) IE81111B1 (en)
IL (1) IL100864A (en)
LU (3) LU90372I2 (en)
MX (1) MX9200509A (en)
NL (2) NL990007I2 (en)
NO (3) NO301585B1 (en)
NZ (1) NZ241515A (en)
PL (1) PL169675B1 (en)
RU (1) RU2053229C1 (en)
SG (1) SG50481A1 (en)
SI (1) SI9210098B (en)
SK (1) SK279261B6 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4224752A1 (en) * 1992-04-11 1994-02-03 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
DE4225756A1 (en) 1992-01-22 1994-03-10 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
DE4224133A1 (en) * 1992-07-22 1994-01-27 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
TW274551B (en) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
DE4207904A1 (en) * 1992-03-12 1993-09-16 Thomae Gmbh Dr K SUBSTITUTED BENZIMIDAZOLYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
US5972990A (en) † 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
DE4315349A1 (en) * 1992-10-06 1994-11-10 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
JP3057471B2 (en) 1993-06-07 2000-06-26 武田薬品工業株式会社 Agent for preventing or treating angiotensin II-mediated diseases
DE4408497A1 (en) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K New bi:phenyl-methyl-benzimidazole derivs.
CA2232663C (en) * 1995-10-06 2008-04-08 Novartis Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
HUP0003982A3 (en) * 1997-10-17 2002-01-28 Eurogene Ltd The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
CN1636561A (en) 1998-12-23 2005-07-13 诺瓦提斯公司 Use of at-1 receptor antagonist for treating diseases associated with an increase of at-1 receptors
EP1013273A1 (en) * 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
DE19901921C2 (en) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
SE9903028D0 (en) 1999-08-27 1999-08-27 Astra Ab New use
AR033390A1 (en) 2000-08-22 2003-12-17 Novartis Ag A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ATTA RECEIVER ANTAGONIST AND A POTENTIATOR OF THE INSULIN SECRETION, THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A PARTS KIT
DE10153737A1 (en) * 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
CZ303145B6 (en) 2002-01-16 2012-05-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing bilayer pharmaceutical tablet containing telmisartan and hydrochlorothiazide
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10335027A1 (en) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis
DE10306179A1 (en) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Composition useful for preventing stroke comprises dipyridamole or its salt, acetyl salicylic acid and an angiotensin II antagonist
DE10314702A1 (en) * 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of telmisartan
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319592A1 (en) * 2003-05-02 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment of diabetic retinopathy with angiotensin II receptor blockers
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB2414019A (en) 2004-05-11 2005-11-16 Cipla Ltd One-step preparation of telmisartan by condensation and hydrolysis
JP2008503595A (en) * 2004-10-15 2008-02-07 テバ ファーマシューティカル インダストリーズ リミティド Preparation of telmisartan
MX2007005129A (en) 2004-10-27 2007-09-11 Daiichi Sankyo Co Ltd Benzene compound having 2 or more substituents.
ITMI20050801A1 (en) 2005-05-03 2006-11-04 Dipharma Spa PROCEDURE FOR THE PREPARATION OF TELMISARTAN
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
WO2007010558A1 (en) * 2005-07-19 2007-01-25 Matrix Laboratories Limited A process for the preparation of telmisartan
ES2246742B1 (en) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. USE OF A DERIVATIVE OF IMIDAZOLE.
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CA2677661A1 (en) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
FR2916757B1 (en) * 2007-05-30 2009-07-17 Servier Lab NOVEL DIAZENIUMDIOLATE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
TWI406850B (en) * 2007-06-05 2013-09-01 Theravance Inc Dual-acting benzoimidazole antihypertensive agents
EA200901619A1 (en) * 2007-07-03 2010-04-30 Крка, Товарна Здравил, Д. Д., Ново Место METHOD OF OBTAINING TELMISARTANA
ATE555099T1 (en) * 2007-12-11 2012-05-15 Theravance Inc DUAL-ACTING BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANHYDROGENIC PRESSURE LOWERING AGENTS
EP2103588A1 (en) 2008-03-20 2009-09-23 Lek Pharmaceuticals D.D. 2'-Halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists
EP2103609A1 (en) 2008-03-20 2009-09-23 Lek Pharmaceuticals D.D. Catalyzed carbonylation in the synthesis of angiotensin ii antagonists
WO2009115585A1 (en) * 2008-03-20 2009-09-24 Lek Pharmaceuticals D.D. Catalyzed carbonylation in the synthesis of angiotensin ii antagonists
WO2009123483A1 (en) 2008-03-31 2009-10-08 Zaklady Farmaceutyczne Polpharma Sa Process for preparation of telmisartan
WO2009135646A2 (en) 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
EP2123648A1 (en) 2008-05-20 2009-11-25 Chemo Ibérica, S.A. A process for the preparation of Telmisartan.
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
WO2010004385A1 (en) * 2008-06-17 2010-01-14 Aurobindo Pharma Limited Process for the preparation of pure 4'-[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid
EP2149566A1 (en) 2008-07-15 2010-02-03 Chemo Ibérica, S.A. A process for the preparation of telmisartan
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010016549A1 (en) 2008-08-06 2010-02-11 協和発酵キリン株式会社 Tricyclic compound
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
ES2415357T3 (en) 2009-06-19 2013-07-25 Krka Tovarna Zdravil, D.D., Novo Mesto Procedure for the preparation of telmisartan
EP2277866A1 (en) 2009-06-22 2011-01-26 Inke, S.A. Process for preparing telmisartan
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (en) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Solid dosage forms containing telmisartan.
EP2305650A1 (en) 2009-09-21 2011-04-06 Chemo Ibérica, S.A. Novel process for the preparation of telmisartan
CN101798300B (en) * 2010-02-23 2013-09-25 陈志龙 N-phenylindole methyl substituted bis-benzimidazole derivative and application thereof in reducing blood pressure and the like
WO2011149438A1 (en) 2010-05-28 2011-12-01 Mahmut Bilgic Combination of antihypertensive agents
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA025946B1 (en) 2010-10-27 2017-02-28 Крка, Товарна Здравил, Д. Д., Ново Место Multilayer pharmaceutical composition comprising telmisartan and amlodipine
CA2846387C (en) 2011-08-26 2016-02-09 Wockhardt Limited Methods for treating cardiovascular disorders
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EA201592263A1 (en) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING
SG10201710705UA (en) 2013-06-21 2018-02-27 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
US9662311B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
EP3027604B1 (en) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
EP2979691A1 (en) 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
JP5871294B1 (en) 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Immediate release oral tablets
KR20170001921A (en) 2015-06-26 2017-01-05 대원제약주식회사 A pharmaceutical composition comprising telmisartan with increased stability and a preparation method thereof
KR20170012703A (en) 2015-07-22 2017-02-03 대원제약주식회사 A pharmaceutical composition comprising telmisartan and a preparation method thereof
US20200316029A1 (en) 2016-05-30 2020-10-08 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
KR101872726B1 (en) 2016-07-28 2018-06-29 주식회사 씨트리 Telmisartan methanesulfonate and pharmaceutical composition comprising the same
AR112265A1 (en) 2017-07-07 2019-10-09 Boehringer Ingelheim Vetmedica Gmbh ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS
JP7257698B2 (en) * 2018-03-30 2023-04-14 オリヅルセラピューティクス株式会社 heterocyclic compound
EP4373474A1 (en) 2021-07-22 2024-05-29 KRKA, D.D., Novo Mesto Bilayer tablet comprising telmisartan and indapamide
CN118265545A (en) * 2021-10-04 2024-06-28 博尔特生物治疗药物有限公司 Asymmetric bisbenzimidazole STING agonist immunoconjugates and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
DE3928177A1 (en) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K BENZIMIDAZOLE, MEDICAMENTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
CA2016710A1 (en) * 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
RU1836357C (en) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Benzimidazole derivatives, their isomers, mixtures of isomers, hydrates or their physiologically bearable salts possessing properties antagonistic to angiotenzine

Also Published As

Publication number Publication date
LU90950I2 (en) 2002-10-30
PL169675B1 (en) 1996-08-30
DE10299029I2 (en) 2006-06-29
NO2011005I1 (en) 2011-05-16
FI105547B (en) 2000-09-15
HU9200355D0 (en) 1992-04-28
NL300095I1 (en) 2002-09-02
IE81111B1 (en) 2000-03-08
EP0502314B1 (en) 1998-05-20
NZ241515A (en) 1994-10-26
HRP940752B1 (en) 2001-02-28
CA2060624C (en) 1999-12-21
JP2709225B2 (en) 1998-02-04
BG62309B2 (en) 1999-07-30
NL990007I1 (en) 1999-06-01
NL990007I2 (en) 1999-07-01
HU211524A9 (en) 1995-11-28
NL300095I2 (en) 2002-11-01
LU91802I2 (en) 2011-05-30
DE59209330C5 (en) 2013-10-31
NO920476L (en) 1992-08-07
HU217084B (en) 1999-11-29
FI920486A (en) 1992-08-07
NO301585B1 (en) 1997-11-17
CH0502314H1 (en) 2012-03-15
RU2053229C1 (en) 1996-01-27
NO2002011I2 (en) 2008-03-03
CS30692A3 (en) 1992-08-12
HK1011145A1 (en) 1999-07-02
JPH04346978A (en) 1992-12-02
DK0502314T3 (en) 1999-03-29
PL293387A1 (en) 1993-01-25
SG50481A1 (en) 1998-07-20
FI920486A0 (en) 1992-02-05
NO920476D0 (en) 1992-02-05
DE10299029I1 (en) 2003-01-23
ES2118095T4 (en) 2011-04-07
SI9210098B (en) 2000-06-30
SK279261B6 (en) 1998-08-05
CA2060624A1 (en) 1992-08-07
DE59209330D1 (en) 1998-06-25
MX9200509A (en) 1992-08-01
EP0502314A1 (en) 1992-09-09
HUT60493A (en) 1992-09-28
IL100864A0 (en) 1992-11-15
AU1070792A (en) 1992-08-13
IE920373A1 (en) 1992-08-12
HRP940752A2 (en) 1997-04-30
ATE166346T1 (en) 1998-06-15
LU90372I2 (en) 1999-05-12
SI9210098A (en) 1994-12-31
CZ287607B6 (en) 2001-01-17
AU655794B2 (en) 1995-01-12
IL100864A (en) 1996-01-19

Similar Documents

Publication Publication Date Title
ES2118095T3 (en) BENZIMIDAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION.
MX154758A (en) PROCEDURE FOR PREPARATION OF SUCCINIMIDE DERIVATIVES
JPS646270A (en) Pyridine derivative and remedy for ulceration containing the same
IL77889A (en) 5-(azolyloxyphenyl-carbamoyl)barbituric acid derivatives,their preparation and their use as helminthicides
ES8506652A1 (en) Dibenzodiazepin derivatives, a process for their preparation and their use as medicaments.
ATE614T1 (en) SUBSTITUTED 2-(BENZOYL)-GLYCINANILIDE DERIVATIVES, THEIR PREPARATION AND USE IN ANXIOLYTIC MEDICINES.
HUP0004590A2 (en) Endothelin antagonist imidazole derivatives and beta receptor blocking agents as combined pharmaceutical preparations
SE8107524L (en) Heterocyclic Associations
ES429864A1 (en) 1,4-Dihydro-4-oxo-pyridylacetamido cephalosporins and their utilization as medicinal agents for combating bacterial infections
HUT51629A (en) Process for producing new, heterocyclically substituted 5,7-dihydro-pyrrolo(3,2-f)-benzoxazole-6-one derivatives as well as pharmaceutical preparations containing such compounds
GB1249512A (en) 0,2,3,4-tetrahydro-7-halo-6-sulfamyl-4-quinazolinones, process for preparing the same and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 502314

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: TELMISARTAN + HIDROCLOROTIAZIDA (MICARDIS PLUS)

Spc suppl protection certif: C200200018

Filing date: 20020806

Free format text: TELMISARTAN (PRITOR)

Spc suppl protection certif: C9900021

Filing date: 19990604

SPCG Supplementary protection certificate granted

Free format text: TELMISARTAN + HIDROCLOROTIAZIDA (MICARDIS PLUS)

Spc suppl protection certif: C200200018

Filing date: 20020806

Expiry date: 20170131

Effective date: 20030901

Free format text: TELMISARTAN (PRITOR)

Spc suppl protection certif: C9900021

Filing date: 19990604

Expiry date: 20131211

Effective date: 20030904